ArticleClinical rheumatology2025
STAT3 rs1053005 (T/C) contributes to Behçet's disease risk and ocular lesions.
Article in Clinical rheumatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionSignal transducer and activator of transcription-3 (STAT3) is a nuclear transcription factor that seems to be involved in the pathogenesis of several autoimmune diseases. Herein, we investigated the association between polymorphisms in the 3'UTR of STAT3 with Behçet's disease (BD) susceptibility in a Tunisian cohort.
methodsThis study included 110 patients with BD and 116 age-unmatched healthy controls. STAT3 rs1053004 and rs1053005 polymorphisms were genotyped by mutagenically separated polymerase chain reaction with newly designed primers.
resultsThe rs1053005 CC genotype and minor C allele were more frequent in patients with BD than in healthy controls (19.1% vs. 7.8% and 37% vs. 26%, respectively). The CC genotype was found to be associated with BD in the co-dominant and recessive models (OR = 2.66, 95%CI = 0.97-7.29, p = 0.05 and OR = 2.67, 95%CI = 1.01-7.02, p = 0.04, respectively). STAT3 rs1053004 was found not to be in the Hardy-Weinberg equilibrium. The G allele was more frequent in BD patients than in healthy controls (36% versus 21%). Moreover, STAT3 rs1053005 minor C allele was significantly associated with severe ocular lesions in BD (OR = 2.76, 95%CI = 1.54-4.94, P
conclusionsSTAT3 rs1053004 and rs1053005 polymorphisms and G-C haplotype are associated with BD risk in our study cohort. The A-C haplotype was significantly associated with severe ocular lesions in BD. Studies in large sample sizes are required to verify and extend these findings. Key points • STAT3 rs1053005 CC genotype is associated with BD susceptibility. • STAT3 rs1053005 C allele is associated with severe ocular manifestations in BD. • The AC haplotype is associated with severe ocular manifestations in BD.
Indexed as
Identifiers
40813733What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.